© 2020 MJH Life Sciences and Cancer Network. All rights reserved.
Myeloproliferative Neoplasms
FDA Approves Luspatercept to Treat Anemia in Patients with Lower-Risk MDS
April 06, 2020
ByKristie L. KahlThe FDA approved the first and only erythroid maturation agent for the treatment of anemia in patients with lower-risk myelodysplastic syndromes.
Patient Outcomes After Stopping Ruxolitinib Remains Dismal in Myelofibrosis
January 17, 2020
ByHannah SlaterThis study highlighted the need for novel therapies in myelofibrosis treatment, given that salvage therapies could potentially improve patient outcomes.
Implications of Mutation Profiling in Myeloid Malignancies-PART 2: Myeloproliferative Neoplasms and Other Myeloid Malignancies
May 15, 2018
ByKelsey Sokol, MD|Douglas Tremblay, MD|Sheena Bhalla, MD|Raajit Rampal, MD|John O. Mascarenhas, MDIn this second part of our two-part review, we discuss the use of mutation profiling in the diagnosis, prognosis, and treatment of patients with myeloproliferative neoplasms and other myeloid diseases.